CWM
BMY.RT

CIBC World Markets’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

CIBC World Markets’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-78,366
Closed -$54K – 1043
2020
Q4 		$54K Buy
78,366
+4,700
+6% +$10K ﹤0.01% 631
2020
Q3 		$166K Hold
73,666
– – ﹤0.01% 574
2020
Q2 		$264K Buy
+73,666
New +$266K ﹤0.01% 564

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

CIBC World Markets's BMY.RT Position: Q1 2021 in Review

CIBC World Markets sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 78,366 shares — an estimated $54K sold.

CIBC World Markets first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $264K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • CIBC World Markets reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • CIBC World Markets sold 78,366 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $54K.
  • CIBC World Markets first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • CIBC World Markets's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $264K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on CIBC World Markets's 13F filing for Q1 2021, filed 7 May 2021.